The association between C-reactive protein (CRP) level and biochemical failure-free survival in patients after radiation therapy for nonmetastatic adenocarcinoma of the prostate

Cancer

Volumn 119, Issue 18, 2013, Pages 3272-3279

  Hall, William A ^a   Nickleach, Dana C ^b   Master, Viraj A ^b   Prabhu, Roshan S ^a   Rossi, Peter J ^a   Godette, Karen ^a   Cooper, Sherri ^a   Jani, Ashesh B ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b EMORY UNIVERSITY   (United States)

Author keywords

C reactive protein and adenocarcinoma of the prostate; C reactive protein and prostate cancer; C reactive protein and radiation therapy; prostate cancer biomarkers

Indexed keywords

BICALUTAMIDE; C REACTIVE PROTEIN; FLUTAMIDE; GOSERELIN; IODINE 125; LEUPRORELIN; PALLADIUM 103; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; BIOCHEMICAL FAILURE FREE SURVIVAL; BRACHYTHERAPY; CANCER RADIOTHERAPY; EXTERNAL BEAM RADIOTHERAPY; FOLLOW UP; GLEASON SCORE; HIGH RISK PATIENT; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LINEAR ACCELERATOR; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE ADENOCARCINOMA; PROSTATECTOMY; RADIOTHERAPY EQUIPMENT; RADIOTHERAPY UNIT; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT PLANNING;

C-REACTIVE PROTEIN AND ADENOCARCINOMA OF THE PROSTATE; C-REACTIVE PROTEIN AND PROSTATE CANCER; C-REACTIVE PROTEIN AND RADIATION THERAPY; PROSTATE CANCER BIOMARKERS;

ADENOCARCINOMA; AGED; ANALYSIS OF VARIANCE; C-REACTIVE PROTEIN; DISEASE-FREE SURVIVAL; HUMANS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84883600886     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28185     Document Type: Article

References (33)

1. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin. 2010; 60: 277-300.
2. Jani AB, Hellman S,. Early prostate cancer: clinical decision-making. Lancet. 2003; 361: 1045-1053. (Pubitemid 36351377)
3. Stamey TA, Yang N, Hay AR, et al. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987; 317: 909-916. (Pubitemid 17147932)
4. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. N Engl J Med. 2004; 350: 2239-2246.
5. de Visser KE, Eichten A, Coussens LM,. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer. 2006; 6: 24-37. (Pubitemid 43053650)
6. Parsonnet J, Friedman GD, Vandersteen DP, et al. Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med. 1991; 325: 1127-1131.
7. Rhodes JM, Campbell BJ,. Inflammation and colorectal cancer: IBD-associated and sporadic cancer compared. Trends Mol Med. 2002; 8: 10-16. (Pubitemid 34044673)
8. Imperial JC,. Natural history of chronic hepatitis B and C. J Gastroenterol Hepatol. 1999; 14 (suppl): S1-5. (Pubitemid 29281857)
9. Coussens LM, Werb Z,. Inflammation and cancer. Nature. 2002; 420: 860-867. (Pubitemid 36019639)
10. Balkwill F, Mantovani A,. Inflammation and cancer: back to Virchow? Lancet. 2001; 357: 539-545. (Pubitemid 32173595)
11. Wang X, Yu J, Sreekumar A, et al. Autoantibody signatures in prostate cancer. N Engl J Med. 2005; 353: 1224-1235. (Pubitemid 41345944)
12. Mercader M, Bodner BK, Moser MT, et al. T cell infiltration of the prostate induced by androgen withdrawal in patients with prostate cancer. Proc Natl Acad Sci U S A. 2001; 98: 14565-14570. (Pubitemid 33121432)
13. De Marzo AM, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999; 155: 1985-1992.
14. Pepys MB, Hirschfield GM,. C-reactive protein: a critical update. J Clin Invest. 2003; 111: 1805-1812. (Pubitemid 38057722)
15. Tatokoro M, Saito K, Iimura Y, et al. Prognostic impact of postoperative C-reactive protein level in patients with metastatic renal cell carcinoma undergoing cytoreductive nephrectomy. J Urol. 2008; 180: 515-519.
16. Hefler LA, Concin N, Hofstetter G, et al. Serum C-reactive protein as independent prognostic variable in patients with ovarian cancer. Clin Cancer Res. 2008; 14: 710-714. (Pubitemid 351231151)
17. Schmid M, Schneitter A, Hinterberger S, et al. Association of elevated C-reactive protein levels with an impaired prognosis in patients with surgically treated endometrial cancer. Obstet Gynecol. 2007; 110: 1231-1236. (Pubitemid 351326063)
18. Polterauer S, Grimm C, Tempfer C, et al. C-reactive protein is a prognostic parameter in patients with cervical cancer. Gynecol Oncol. 2007; 107: 114-117. (Pubitemid 47464551)
19. Nozoe T, Saeki H, Sugimachi K,. Significance of preoperative elevation of serum C-reactive protein as an indicator of prognosis in esophageal carcinoma. Am J Surg. 2001; 182: 197-201. (Pubitemid 32907362)
20. Legouffe E, Rodriguez C, Picot MC, et al. C-reactive protein serum level is a valuable and simple prognostic marker in non Hodgkin's lymphoma. Leuk Lymphoma. 1998; 31: 351-357. (Pubitemid 29033956)
21. Nozoe T, Matsumata T, Kitamura M, et al. Significance of preoperative elevation of serum C-reactive protein as an indicator for prognosis in colorectal cancer. Am J Surg. 1998; 176: 335-338. (Pubitemid 28514444)
22. Tartour E, Dorval T, Mosseri V, et al. Serum interleukin 6 and C-reactive protein levels correlate with resistance to IL-2 therapy and poor survival in melanoma patients. Br J Cancer. 1994; 69: 911-913. (Pubitemid 24140673)
23. Saito K, Kihara K,. C-reactive protein as a biomarker for urological cancers. Nat Rev Urol. 2011; 8: 659-666.
24. Beer TM, Lalani AS, Lee S, et al. C-reactive protein as a prognostic marker for men with androgen-independent prostate cancer: results from the ASCENT trial. Cancer. 2008; 112: 2377-2383.
25. Prins RC, Rademacher BL, Mongoue-Tchokote S, et al. C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol. 2012; 30: 33-37.
26. Ito M, Saito K, Yasuda Y, et al. Prognostic impact of C-reactive protein for determining overall survival of patients with castration-resistant prostate cancer treated with docetaxel. Urology. 2011; 78: 1131-1135.
27. McArdle PA, Qayyum T, McMillan DC,. Systemic inflammatory response and survival in patients with localised prostate cancer: 10-year follow-up. Urol Int. 2010; 85: 482.
28. Di Napoli M, Elkind MS, Godoy DA, et al. Role of C-reactive protein in cerebrovascular disease: a critical review. Expert Rev Cardiovasc Ther. 2011; 9: 1565-1584.
29. Abramowitz MC, Li T, Buyyounouski MK, et al. The Phoenix definition of biochemical failure predicts for overall survival in patients with prostate cancer. Cancer. 2008; 112: 55-60.
30. Yu CX, Li XA, Ma L, et al. Clinical implementation of intensity-modulated arc therapy. Int J Radiat Oncol Biol Phys. 2002; 53: 453-463. (Pubitemid 34522111)
31. Casas JP, Shah T, Hingorani AD, et al. C-reactive protein and coronary heart disease: a critical review. J Intern Med. 2008; 264: 295-314.
32. Albert MA, Danielson E, Rifai N, et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA. 2001; 286: 64-70. (Pubitemid 32606333)
33. Nakashima J, Kikuchi E, Miyajima A, et al. Simple stratification of survival using bone scan and serum C-reactive protein in prostate cancer patients with metastases. Urol Int. 2008; 80: 129-133. (Pubitemid 351440504)